Protagenic Therapeutic -CW25PTIXWPreferred / convertible
13F holders, Q3 2025 (September 30)4holders
0new positions
0sold out
$0.03avg. 13F price*
At the end of Q3 2025, 4 institutions reported holding Protagenic Therapeutic -CW25 (PTIXW) in their 13F filings, unchanged from Q2 2025. 0 opened new positions and 0 sold out. The largest holders were Clear Street Group Inc. ($3K), Susquehanna International Group, LLP ($2K) and Two Sigma Securities, LLC ($316).
- Company
- Protagenic Therapeutic -CW25
- CUSIP
- 74365N111
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q2 2025 → Q3 2025: 63,328 shares bought, net +63,328 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Clear Street Group Inc. | — | — | 100,000 | $3K |
| Susquehanna International Group, LLP | — | Add +245.2% | 87,596 | $2K |
| Two Sigma Securities, LLC | — | Add +9.9% | 12,352 | $316 |
| Bank of America Corp. | — | No change | 100 | $2 |
"% of holder's portfolio" is PTIXW's weight in each manager's 13F, not the share of Protagenic Therapeutic -CW25 the manager owns.